Quest Diagnostics (DGX) announced an advanced pharmacogenomic laboratory test service designed to help providers understand the patient’s individual genetic response to select drug therapies. This innovative offering aims to help providers determine appropriate medication on selection and dosing. It utilizes PGx information across a wide range of medical specialties including psychiatry, neurology, cardiology, oncology, rheumatology, pain management, and the transplant recipient space.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics’ Strategic Expansion with Corewell Health Drives Buy Rating
- Quest Diagnostics and Corewell Health form joint venture in Michigan
- Figma initiated, Okta upgraded: Wall Street’s top analyst calls
- Quest Diagnostics: FDA grants Breakthrough Device Designation for Haystack MRD
- Quest Diagnostics downgraded to Neutral from Outperform at Baird